
David Paterson
@davidantibiotic
Infectious Diseases Physician. Founder of MERINO clinical trials network. Director of ADVANCE-ID. Interests - clinical trial design, new antimicrobial agents.
ID: 3010719595
06-02-2015 01:26:28
2,2K Tweet
4,4K Followers
718 Following








Just out.! Led by Mariana Barosa we revisit target trial emulation. We show, under a variety of scenarios, real world evidence is actually MORE EXPENSIVE to generate than randomized evidence See tables & figures in thread VKPrasadLab



Brad Spellberg Beg to differ! The world is bigger than the US, and outside Nth America most ID specialists prefer(ed) ASPs. Yes guidelines and expert opinion are part of the reason. BUT lack of RCTs was a crucial part.

Brad Spellberg We should not change or base our practice on observational studies. They are often wrong. In this case they were not, but the only was of knowing that for sure is to remove bias by doing big RCTs

ARLG Network member David Paterson gave a keynote at #ESCMIDGlobal, Asia: An AMR hot zone. He discussed the antimicrobial resistance crisis in Asia and strategies to address this global health concern. Learn how the #ARLGnetwork is working to fight #AMR: arlg.org





Jom join Steven Tong and Patrick Harris as they discuss the challenges of post-trial access to antibiotics — a frustrating reality for many LMICs, including Malaysia! #AccessToMedicines Global Antibiotic R&D Partnership (GARDP) Dr Syamhanin Adnan AdamJ Rahela ambaras khan MyICID Steven Lim revive.gardp.org/post-licensing…




Another brilliant episode on #communicable hosted by Dr Erin McCreary & Dr Angela Huttner from practice changing SNAP Trial with Steven Tong & Joshua Davis on the results, which was recently presented at #ESCMIDGlobal2025. ESCMID CMI Communications
